Regis A. Vilchez

Regis A. Vilchez, M.D., Ph.D., was a faculty member of the Departments of Medicine and Molecular Virology at Baylor College of Medicine. Dr. Vilchez early research worked was focused on DNA tumor viruses and their encoded oncogenes. Over the course of 17 years at different biopharmaceutical companies, Dr. Vilchez served in multiple leadership roles in the evaluation, clinical development, and NDA submission of different antiviral drugs for HIV and HCV in the US, EU, Japan and China. Dr. Vilchez was most recently Vice President & Global Head of Clinical Development at Mallinckrodt Pharmaceuticals where he was responsible of translation science and clinical development teams conducting programs and their respective regulatory filings for small molecules and biologics for rare diseases and/or orphan indications. Dr Vilchez received his Ph.D. from the Graduate School of Biomedical Sciences at Baylor College of Medicine and M.D. from Universidad Autonoma de Centro America. In addition, he completed an internal medicine residency at Robert Wood Johnson Medical School, a clinical infectious diseases fellowship at the University of Pittsburgh, and a molecular virology fellowship at Baylor College of Medicine.